Figure 3.

Andrographolide inhibits constitutive and IL-6–induced Stat3, MAPK, and AKT activity of human prostate cancer cells. (A) DU145 cells that express IL-6 autocrine loop were treated with increasing doses of andrographolide for 24 hours, and cell lysates were collected and subjected to Western blot analysis using the antibodies as indicated. (B) LNCaP cells that lack IL-6 but express IL-6 receptor and gp130 were pretreated with andrographolide for 4 hours. Cells were then stimulated with 10 ng/mL of IL-6 for 30 minutes after pretreatment with andrographolide. Whole cell lysates were prepared and subjected to Western blot analysis using antibodies as indicated.